59 related articles for article (PubMed ID: 29773504)
21. Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
Liu H; Wu J; Ge Y; Li A; Li J; Liu Z; Xu Y; Xu Q; Li Y
Bioorg Med Chem; 2018 Mar; 26(5):1050-1061. PubMed ID: 29426629
[TBL] [Abstract][Full Text] [Related]
22. Development of peptidomimetic boronates as proteasome inhibitors.
Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
[TBL] [Abstract][Full Text] [Related]
24. Development of novel proteasome inhibitors based on phthalazinone scaffold.
Yang L; Wang W; Sun Q; Xu F; Niu Y; Wang C; Liang L; Xu P
Bioorg Med Chem Lett; 2016 Jun; 26(12):2801-2805. PubMed ID: 27158142
[TBL] [Abstract][Full Text] [Related]
25. Enantioselective synthesis of adamantylalanine and carboranylalanine and their incorporation into the proteasome inhibitor bortezomib.
de Bruin G; Mock ED; Hoogendoorn S; van den Nieuwendijk AM; Mazurek J; van der Marel GA; Florea BI; Overkleeft HS
Chem Commun (Camb); 2016 Mar; 52(21):4064-7. PubMed ID: 26894389
[TBL] [Abstract][Full Text] [Related]
26. Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib.
Xu Y; Yang X; Chen Y; Chen H; Sun H; Li W; Xie Q; Yu L; Shao L
Bioorg Med Chem Lett; 2018 Jul; 28(12):2148-2152. PubMed ID: 29773504
[TBL] [Abstract][Full Text] [Related]
27. Discovery of Natural Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives.
Wang H; Yang Q; Dou QP; Yang H
Curr Protein Pept Sci; 2018 Feb; 19(4):358-367. PubMed ID: 28079010
[TBL] [Abstract][Full Text] [Related]
28. The therapeutic potential of microbial proteasome inhibitors.
Momose I; Kawada M
Int Immunopharmacol; 2016 Aug; 37():23-30. PubMed ID: 26589840
[TBL] [Abstract][Full Text] [Related]
29. Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview.
Guedes RA; Serra P; Salvador JA; Guedes RC
Molecules; 2016 Jul; 21(7):. PubMed ID: 27438821
[TBL] [Abstract][Full Text] [Related]
30. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Xi J; Zhuang R; Kong L; He R; Zhu H; Zhang J
Eur J Med Chem; 2019 Nov; 182():111646. PubMed ID: 31521028
[TBL] [Abstract][Full Text] [Related]
31. Discovery and development of second-generation proteasome inhibitors.
Kirk CJ
Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
[TBL] [Abstract][Full Text] [Related]
32. Proteasome inhibitors.
Cvek B
Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
[TBL] [Abstract][Full Text] [Related]
33. The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.
Citrin R; Foster JB; Teachey DT
Expert Rev Hematol; 2016 Sep; 9(9):873-89. PubMed ID: 27447436
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
